AveXis Obtains $65,000,000 Series D Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    4925 Greenville Avenue Dallas, TX 75206 USA
  • Company Description
    AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    The proceeds will be used to advance the company’s ongoing spinal muscular atrophy (SMA) clinical program and expand key operational capabilities.
  • M&A Terms
  • Venture Investor
    T. Rowe Price
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    Roche Venture Fund
  • Venture Investor
  • Venture Investor
    Janus Capital
  • Venture Investor
    Adage Capital Management
  • Venture Investor
    RA Capital
  • Venture Investor
    QVT Fund
  • Venture Investor
    Rock Springs Capital
  • Venture Investor
    Foresite Capital
  • Venture Investor
    Tavistock Life Sciences

Trending on Xconomy